PR Newswire
SAN DIEGO and PENNINGTON, N.J., June 28, 2018
SAN DIEGO and PENNINGTON, N.J., June 28, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, provided an update of key value-creating milestones for the second half of 2018 and a review of its year-to-date accomplishments.
"We believe we can unlock the larger checkpoint market across multiple cancer types by turning 'cold tumors' to 'hot tumors' with our intratumoral IL-12 immunotherapy or 'TAVO.' Our data have demonstrated TAVO's ability to do so by recruiting more tumor infiltrating lymphocytes (TILs) into the tumors. In doing so, TAVO can pave the way for checkpoints to be effective in the largest, but still unresponsive, segment of the checkpoint market," said Daniel J. O'Connor, President and Chief Executive Officer of OncoSec.
ANTICIPATED 2018 MILESTONES
OncoSec anticipates to achieve the following clinical and operational milestones during the second half of 2018:
Clinical Milestones for TAVO
TAVO for Metastatic Melanoma
TAVO for Triple Negative Breast Cancer (TNBC)
TAVO for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
New Product Candidate
Expanding Clinical Pipeline beyond TAVO
Commercially Ready Generator
Business Development
FIRST HALF 2018 HIGHLIGHTS
OncoSec achieved important clinical, operational and business-development milestones during the first half of 2018, highlighted by the following accomplishments:
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "can," "may," "will," "suggest," "look forward to," "potential," "understand," and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: uncertainties inherent in pre-clinical studies and clinical trials, such as the ability to enroll patients in clinical trials and the risk of adverse events; unexpected new data, safety and technical issues; our ability to raise additional funding necessary to fund continued operations; and the other factors discussed in OncoSec's filings with the Securities and Exchange Commission.
Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
[email protected]
Media Relations:
Janine McCargo / David Schemelia
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
[email protected]
[email protected]
View original content with multimedia:http://www.prnewswire.com/news-releases/oncosec-provides-outlook-for-second-half-of-2018-300672914.html
SOURCE OncoSec Medical Incorporated
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member